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ABSTRACT

THE ROLES OF CARDIOVASCULAR DISEASE AND DEPRESSION IN THE
RELATIONSHIP BETWEEN RESPIRATORY DISEASE AND
NEUROPSYCHOLOGICAL FUNCTIONING IN OLDER ADULTS

Alexander J. Gordon

The pathophysiology of severe respiratory diseases, such as asthma and chronic
obstructive pulmonary disease (COPD), supports the theory that oxygen deprivation to
the brain may impact the brain’s execution of cognitive functions. Imaging studies also
suggest that neuroanatomical changes in areas of the brain responsible for cognitive
processes may be associated with respiratory diseases. Research in this area has failed to
conclude definitively, especially in an older adult population, which is more likely to
experience comorbid depression and cardiovascular disease, universally acknowledged
predictors of poorer cognitive performance, the extent of the relationship between
respiratory illness and cognitive functioning. The current study investigated the
association between respiratory disease with cognitive performance in older adults, also
considering the relative impact of cardiovascular disease and depression. Functioning
was examined globally and in the individual domains of psychomotor functioning and
verbal ability. Physiological measures of disease were also explored for potential
relationships with cognition. Results suggest that depression was consistently associated
with poorer performance across cognitive domains, whereas cardiovascular disease was

primarily associated with reduced functioning in psychomotor tasks. After accounting for
these effects, no additional association between respiratory disease and cognitive
functioning was identified, with the possible exception of COPD relating to enhanced
verbal ability. None of the physiological measures obtained were found to correlate with
cognition in this research. Explanations and implications of these findings are discussed.
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1
Introduction

The two most common respiratory diseases are asthma and chronic obstructive
pulmonary disease (COPD). Asthma is a relatively common chronic disease that affects
over 8% of adults in the United states (Centers for Disease Control and Prevention,
2018). Common asthma symptoms include chest tightness, coughing or wheezing, and
shortness of breath. A frequent physiological effect of asthma is thickening of the
muscles comprising the airway, resulting in reduced airflow to the lungs. Certain
conditions, such as stress, excessive activity, and infection, may subject individuals with
asthma to hypoxemia, a low blood-oxygen level, which interferes with oxygen supply to
vital organs, including the brain. Asthma attacks that increase the severity of asthma
symptoms can create hypoxic conditions, resulting in potentially dangerous levels of
oxygen deprivation. Chronic obstructive pulmonary disease (COPD), whose etiology is
often attributed to smoking, or exposure to other pollutants, can be more severe than
asthma, as it is chronic and progressive in nature. Diseases included under the umbrella
of COPD are emphysema, a disease in which air is trapped in damaged parts of the lung
preventing proper airflow, and chronic bronchitis, chronic inflammation of the channel
that brings air to and from the lungs. Although COPD has a lower prevalence than asthma
of just over 4% (Doney et al., 2014), both share common symptomatology,
pathophysiology, and the potential for functional impairment due to oxygen deprivation.
Other respiratory diseases, such as sleep apnea, a condition that manifests in abnormal
breathing patterns, often with pauses that delay oxygen intake, and pulmonary fibrosis, a
condition in which scar tissue on the lung restricts oxygen flow, also result in decreased
oxygenation. This rationale is the general basis for scientific research investigating
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cognitive functioning in people with respiratory diseases. Cerebral oxygenation is the fuel
for brain functions, especially motor and higher-order processes.

The association between respiratory disease and cognitive functioning does not
merely stem from a theoretical argument. Neuroimaging research has demonstrated that
patients with asthma and COPD, the two most common respiratory illnesses, can yield
structural changes in the brain that may influence execution of cognitive abilities,
especially in hippocampal and gray matter areas, which are particularly sensitive to
oxygen deprivation (Caldera-Alvarado et al., 2013; Dodd et al., 2012; Esser et al., 2016;
Moss et al., 2005). Additionally, corticosteroid use is a common form of treatment for
both asthma and COPD, which has been implicated in cognitive impairment by way of
affecting the hippocampus and frontal lobe (Belanoff et al., 2001; Brown et al., 1999;
Carlson et al., 2017). These areas are particularly noteworthy as they are associated with
executive functions, learning, memory, spatial perception, language, and emotions
(Leupoldt et al., 2011; Lezak et al., 2004). Related structural changes in the brain
establish an even stronger rationale for investigating neuropsychological functioning in
this population. It should be noted, however, that some have found that while use of
corticosteroids may have a negative impact on executive functioning and memory, it has
been associated with a positive effect on expressive language and some other functions
(Bozek et al., 2010; Prado & Crowe, 2019).

A challenge in this line of research is identifying the relative impact of comorbid
psychological and medical conditions in the relationship between respiratory disease and
cognitive performance. There is an abundance of literature documenting a high
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prevalence of depression and anxiety among patients with asthma or COPD (Briraatek et
al., 2015; Del Giacco et al., 2016; Han, Forno, Marsland, Miller, & Celedón, 2016;
Yohannes, Willgoss, Baldwin, & Connolly, 2010) and because anxiety and depression
are known to negatively impact neuropsychological functioning even in the absence of
asthma or COPD (Geda et al., 2014; Rock et al., 2014), it is important to ascertain
whether respiratory disease affects functioning in a direct path, or whether these
psychological comorbidities account for the effect. Asthma and COPD have also been
shown to co-occur with numerous medical comorbid diseases, most commonly
cardiovascular and metabolic diseases and especially in elderly populations (Soriano et
al., 2005; Su et al., 2016; Tsai et al., 2012; Wardzyńska et al., 2015; Yáñez et al., 2014).
Similarly, cardiovascular, cerebrovascular, and metabolic diseases, such as hypertension,
congestive heart failure, stroke, and diabetes, to name a few, have also been associated
with cognitive impairment, further complicating the process of evaluating their relative
impact on cognitive functioning in the presence of asthma or COPD (McCrimmon et al.,
2012; Waldstein & Elias, 2015).

Research to date on the relationship between respiratory disease and
neuropsychological functioning is limited, especially with older adult populations (Irani
et al., 2017; Tsai et al., 2012). However, numerous factors suggest that this older adult
subset of the population deserves particular focus in the study of cognition among
respiratory disease patients. Firstly, the above-mentioned comorbidities are more
common in an older population, increasing the potential risk for cognitive impairment.
Additionally, it is important to consider if and how cognitive processing among older
patients with respiratory disease differs from normal cognitive aging among healthy older
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adults (Irani et al., 2017). Some studies have also pointed to increased severity of
asthma/COPD among the elderly, and an increased likelihood of consequential reduced
cognitive functioning among older adults (Caldera-Alvarado et al., 2013; Dodd, 2015;
Irani et al., 2017; Ray et al., 2015; Rusanen et al., 2013; Zein et al., 2015). One scientific
approach suggests that asthma among older adults manifests in a manner phenotypically
distinct from childhood asthma and that it is essentially classified as the same disease as
COPD (Yáñez et al., 2014). Thus, the elderly asthma/COPD cohort becomes an important
one to study in the context of both disease severity, as well as increased likelihood of
psychological and medical comorbidities.

Research findings addressing the impact of respiratory disease (most commonly
investigating asthma, COPD, or both) on neuropsychological functioning in the elderly
are not only limited, but inconsistent. To summarize, some studies found minimal or no
relationship between asthma/COPD and neuropsychological performance in the elderly
(e.g., Caldera-Alvarado et al., 2013; Dodd, 2015; Moss et al., 2005; Salık et al., 2007),
and others identified that asthma/COPD patients exhibited poorer cognitive performance
than healthy counterparts (e.g., Crişan et al., 2014; Hung et al., 2009; Mourad et al.,
2017; Torres-Sánchez et al., 2015). Some of these studies used a single, brief test of
global cognition as a proxy for neuropsychological functioning rather than several scales
that span multiple cognitive domains. Additionally, the impact of most of these studies is
limited due to either small sample size, lack of a comparison group to the asthma or
COPD groups, or a failure to account for the effects of relevant comorbidities. For
example, cardiovascular disease has long been linked with poor cognitive outcomes,
attributed to some of the risk factors that accompany the disease, subclinical strokes, and
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more recently, structural brain changes due to cardiovascular disease (Johansen et al.,
2020; Leritz et al., 2011). Specific deficits have been noted with higher-order functions,
such as cognitive flexibility and processing speed, as assessed with the Digit Symbol Test
(Hajjar et al., 2011). Others also found that cardiac health was associated with some
higher-order cognitive processes, such as psychomotor tasks, executive functioning, and
global cognition, but also that it was seldom associated with verbal processes. (Crichton
et al., 2014). Additionally, psychological comorbidities like depression and anxiety have
also been associated with poorer cognitive performance in the elderly, especially in the
domains of processing speed, memory, attention, and executive control (Beaudreau &
O’Hara, 2009; Geda et al., 2014; Rock et al., 2014; Shimada et al., 2014). The
interactions of comorbidities in their relationships with each other and with cognitive
functioning increases the complexity of investigating relative effects of each factor.
Research evaluating the link between respiratory disease and cognitive functioning must
properly execute sound methodological strategy as well as account for the possible
effects of these comorbidities in order to draw translatable conclusions.

In a preliminary study, the current author investigated group differences in
neuropsychological functioning between asthma, COPD, and comparison groups of older
adults (Gordon, 2019). Using a quasi-experimental design, with a large sample size and
numerous neuropsychological measures spanning various cognitive domains, the research
did not reveal meaningful group differences in any of the domains assessed (executive
functioning, complex attention, verbal memory, language, visual construction, and
psychomotor functioning). However, despite the absence of statistically meaningful
group differences, an observable trend suggested that COPD patients may have
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performed more poorly than controls on tasks in which the cognitive complexity or
psychomotor demands increased from trial to trial in the task (e.g., when using nondominant hand versus the dominant hand). This research, however, did not account for
the psychological and medical comorbidities known to influence cognitive functioning
that may have impacted the results. Additionally, unlike some of the earlier work in this
area, physiological measures of respiratory disease function were not reviewed in the
context of neuropsychological performance.

The aims of the current study were: 1) to build upon previous research on the
impact of respiratory disease on neuropsychological functioning in older adults by
evaluating the role of key psychological and medical comorbidities most likely to impact
functioning (i.e., cardiovascular diseases and depression); 2) To examine the impact of a
broad group of respiratory diseases with similar pathophysiology (e.g., including sleep
apnea, pulmonary fibrosis) on cognition and to further explore differences between
asthma and COPD subgroups in comparison; 3) To explore patterns of physiological
differences between groups and their potential relationship with cognitive performance
using measures of blood pressure and oxygen saturation levels. In light of research
suggesting that respiratory illness is more likely to affect more cognitively demanding
aspects of neuropsychological functioning, especially tasks requiring cognitive flexibility
and psychomotor functions (e.g., Irani et al., 2017; Moss et al., 2005; Rajabi, Keshavarz,
Dehghani, Keshavarz, & AliMoradi, 2018), focus was devoted to performance on such
tests.
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Hypotheses

1) It was expected that ratings for both psychological disorders (i.e., depression and
anxiety) would correlate negatively with neuropsychological measures, indicating
that more severe depression and anxiety would reflect poorer cognition.
2) All neuropsychological test measures were expected to correlate with one another,
allowing for examination of a global cognition score in addition to more specific
domains.
3) It was expected that both cardiovascular disease and depression would relate to
performance on global cognition, psychomotor functioning, and verbal ability, such
that those with self-reported cardiovascular disease and higher depression scores
would perform more poorly in these domains than those in a reference group.
Literature supports a hypothesis that cardiovascular disease would have the greatest
impact in the domain of psychomotor functioning.
4) It was also expected that after accounting for the effects of cardiovascular disease and
depression, that respiratory disease would be related to poorer performance in all
three domains. It was further anticipated that COPD would be more strongly
implicated over asthma in poorer performance due to COPD’s more severe
symptomatology.
5) Lower oxygen and higher blood pressure levels were expected to correlate with
poorer performance in all cognitive domains.
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Method

The data for this study was collected from participants of the Memory Education
and Research Initiative (MERI), an ongoing clinical research program that measures a
wide range of medical, behavioral, cognitive, and demographic data (Reichert et al.,
2015). Participants are typically referred to the MERI for neuropsychological testing
secondary to subjective memory complaints or concerns regarding a family history of
dementia. Many, if not most of the MERI participants, however, are found not to be
cognitively impaired from a clinical standpoint and comprise most of the research
subjects included in this study. More detailed information regarding the participant pool
has been previously published in a book chapter describing the MERI model (Reichert et
al., 2015). Participants under the age of 60 years were excluded from this study consistent
with previous studies of older adult cohorts using similar age cutoffs. In preliminary
research (Gordon, 2019), subjects considered to be cognitively impaired as determined by
Mini Mental State Examination (MMSE; Folstein, Folstein, & McHugh, 1975) scores
below 24, a conventional cutoff for this measure (Lezak et al., 2004), were excluded. The
current research aimed to enhance methodology by removing the MMSE cutoff criterion,
recognizing that physical disease may facilitate cognitive impairment and by excluding
those with clinical impairment, the overall data may have been misrepresented.

Participants

After excluding participants below 60 years old and who did not complete any
neuropsychological test, a total of 969 participants were included, comprising groups of
those without cardiovascular or respiratory disease, those with both disease types, those
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with only cardiovascular disease, the largest subgroup, and those with only respiratory
disease. See Figure 2 for a visual representation of these groups. Participants had mean
age of 74 years, were mostly female (60%), and attained 15 years of education, on
average. Not all participants completed the full protocol of cognitive tests due to either
physical or cognitive handicap, refusal, or because tests were only introduced to the study
protocol at a later time

Procedures

Study procedures have been approved by the institutional review boards of the
Nathan S. Kline Institute for Psychiatric Research and St. John’s University. A detailed
account of operations of the MERI can be found in the MERI book chapter (Reichert et
al., 2015). Informed consent was obtained from all participants at initial contact. The
components of the MERI that contributed to the current research include a detailed
medical history, a brief medical exam, and a comprehensive neuropsychological battery.
All medical data, including diagnoses of respiratory and cardiovascular disease and other
medical history, as well as demographic information, were obtained by medical
professionals via participant self-report during the intake process. Physiological
measures, including blood-oxygen, blood pressure, and pulse, among other vital signs,
were also measured at this time. Following intake, the neuropsychological test battery
was administered by a trained psychometrician in a quiet room devoted to testing
procedures. Following medical intake and neuropsychological testing, all MERI
participants participated in a clinical interview with a geriatric psychiatrist.

10
Data collected as part of the MERI were entered, stored, and cross-checked with
paper files in a secure database. After all MERI visits, brief reports were compiled and
reviewed in consultation with a clinical neuropsychologist and geriatric psychiatrist and
results were mailed to participants.

Neuropsychological Measures

Descriptions of all neuropsychological tests administered as part of the MERI
program are contained in the MERI book chapter (Reichert et al., 2015). Brief
descriptions of the tests examined as part of the current study are provided below.

Mini Mental State Examination (MMSE; Folstein et al., 1975). Used as a
measure of global cognitive functioning and a cutoff criterion (scores < 24) for cognitive
impairment. The MMSE is a brief assessment that screens for potential problems in the
areas of orientation, registration, attention and calculation, recall, and language. The test
consists of both verbal and paper-and-pencil responses. The maximum score, indicating
higher performance, is 30 points.

Rey Auditory Verbal Learning Test (AVLT; Rey, 1958). Used as a measure of
verbal memory, the AVLT encompasses five learning trials of a 15-word list, yielding a
total recall score with a maximum of 75 words, an immediate test of uncued recall of
words after an “interference” word list is presented, a delayed test of uncued recall of the
original words after a 20-25 min delay, and a recognition task involving cued, multiplechoice recall of the original word list. Scores represent the number of words accurately
recalled.
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Boston Naming Test (abridged; Kaplan et al., 1983). An abridged version of a
60-item confrontation naming measure requires respondents to name what they see in 30
drawings, which range from familiar objects to less familiar ones. If a participant fails to
produce a response, a semantic cue is provided, followed by a phonetic cue if the
respondent has difficulty naming even with a semantic cue. This test is used to assess
language ability, with scores representing the number of items correctly named out of 30.

Digit Symbol Substitution (Wechsler, 1939). A timed coding test in which
participants are to use a key with paired numbers and symbols to complete a grid, which
has numbers in the top portion and empty boxes in the lower portion, by filling in the
corresponding symbols into the empty boxes. This test is used to measure both complex
attention and processing speed, as well as serve as a proxy for executive functioning.
Scores represent the number of symbols accurately transcribed.

Grooved Pegboard (Lafayette Instruments; Model 32025). In this timed task,
participants are asked to use metal pegs with one notched side to fill an arrangement of
five rows with five slots each. Slots are oriented in different directions, requiring
participants to maneuver pegs to fit accordingly. Scores on this test indicate the amount
of time (in seconds) needed to complete the task. This test has separate trials for
dominant and non-dominant hands. Grooved Pegboard is a more complex task of
psychomotor functioning and is also a correlate of general cognitive ability. Because
higher scores indicate poorer performance, scores were reversed for statistical analyses.

Trail Making Test A (TMTA) & B (TMTB; Reitan, 1992). This test has two
parts. Part A has participants draw lines sequentially connecting a series of circles with
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numbers. Part A tests for attention and visual tracking, but also letter sequencing. The
more complex Part B requires drawing lines sequentially, but this time alternating
between both numbers and letters. Part B measures complex attention and the executive
function of cognitive flexibility. Scores on this test indicate the amount of time (in
seconds) needed to complete the task. Because higher scores indicate poorer
performance, scores were reversed for statistical analyses.

Verbal Fluency (FAS; Spreen & Benton, 1977) and Category Fluency
(Animals; Moms et al., 1989). In Verbal Fluency (FAS), also known as the Controlled
Oral Word Association Test (COWAT), participants are asked in three different trials to
produce as many words as they can in 1 min that begin with the letters F, A, and S,
respectively. Credit is not awarded for proper nouns, numbers, and the same word with a
different suffix. In Category Fluency (Animals), participants are asked to name as many
animals as they can in 1 min. These tests are associated with both executive functioning
and the verbal fluency aspect of language. Scores on these tests indicate the amount of
valid words produced in the allotted 1 min.

Vocabulary. This test asks participants for definitions of words, ranging in
difficulty level. It is an assessment of language attainment. Definitions are scored
according to precision and quality, with higher scores indicating better performance.

Although several of these tests may represent multiple cognitive domains, scores
were aggregated to assess three core domains: global cognition, psychomotor
functioning, and verbal ability. Categorization of domains was based largely on theory
and precedents. Global cognition is an aggregate of scores for all neuropsychological
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tests (excluding MMSE), representing a generalized level of overall cognitive
performance in a more comprehensive manner than brief screeners like the MMSE that
only contain one or several individual test items to represent domains. The
psychomotor/executive functioning domain is an aggregate of scores of tests of higherorder processing and psychomotor functioning (e.g., cognitive flexibility, processing
speed, manual dexterity) and includes the following tests: Digit Symbol, Trail Making
Test B, and Grooved Pegboard. Verbal ability is an aggregate of test scores that have a
verbal or language component (e.g.., verbal memory and learning, verbal fluency,
confrontation naming, letter sequencing) and includes the following tests: AVLT total
recall, Verbal Fluency, Category Fluency, Trail Making Test A, Vocabulary, and Boston
Naming. A visual depiction of domain aggregate scores can be found in Figure 1.

Psychological Measures

Depression. Multiple valid and reliable measures of depression were
administered as part of the MERI program, including the Hamilton Depression Rating
Scale (HAM-D; Hamilton, 1960), Beck Depression Inventory (BDI; Beck et al., 1996),
Profile of Mood States (POMS; McNair et al., 1971), which has a Depression subscale,
and the Geriatric Depression Scale (GDS; Yesavage et al., 1982). Aggregate scores of
depression scales were used for participants who completed multiple scales.

Anxiety. Scales of anxiety were also administered as part of the MERI, including
the Hamilton Anxiety Rating Scale (HAM-A; Hamilton, 1959), Beck Anxiety Inventory
(BAI; Beck et al., 1988), and Profile of Mood States (POMS; McNair et al., 1971), which
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has a Tension-Anxiety subscale. Anxiety scale scores were also aggregated for
participants who completed multiple scales.

Medical Diseases

Cardiovascular. Cardiovascular disease includes a wide range of heart-related
conditions and illnesses. Some of the most common ones endorsed by participants
include: hypertension, history of heart attack, atrial fibrillation, stents or pacemakers,
arrythmia, coronary artery disease, and congestive heart failure. Cardiovascular disease
was measured by patient self-report during intake.

Respiratory. Respiratory disease in the current study includes self-reported
history of the following: asthma, COPD, sleep apnea, and pulmonary fibrosis.
Respiratory disease was measured by patient self-report during intake.

Data Analytic Strategy

Group differences among demographic variables were tested with either Chisquare tests or independent samples t-tests. Zero-order correlations were used to assess
for relationships between psychological, neuropsychological, and medical disease
variables to identify variables of interest, test for multicollinearity, and justify
aggregation of related scales. To test for relationships between independent variables and
dependent variables, hierarchical multiple regressions were conducted for all three
cognitive domains in three variations to allow for examination of groups that include all
respiratory diseases, asthma alone, and COPD alone. On occasion, test scores presented
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with extreme values. In these instances, winsorization was used to rectify the outlying
data. All analyses were conducted using IBM SPSS Statistics Version 25.
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Results

For possible differences between the respiratory and reference groups on
demographic variables that relate to cognition, Chi-square tests and independent samples
t-tests were conducted to evaluate group differences in gender, age, and years of formal
education. The tests revealed no meaningful differences between the groups with respect
to gender (p = .88), age (p = .23) and years of education (p = .42). Therefore, these
demographic variables were omitted from further analyses. Additionally, aggregate
anxiety scores did not demonstrate a meaningful relationship with either cardiovascular
or respiratory disease and did not account for group differences (p > .05). It was,
therefore, not implicated as a variable that suppressed the relationship between
respiratory disease and cognition. As a result, anxiety was omitted from the primary
analyses (i.e., regression analyses). Means and standard deviations for
neuropsychological tests in raw score form and mean z-scores for aggregate depression
and anxiety are provided in Table 1 for the whole sample, the respiratory disease group,
and the cardiovascular disease group. All aggregate scores (i.e., depression, anxiety,
cognitive domains) were calculated by converting raw scores of individual tests to zscores, then adding scores together and taking the mean for each participant.

Although anxiety did not correlate with either disease type, it did correlate
meaningfully with depression (r = .83, p < .001) and weakly, but meaningfully, with the
cognitive domains of global cognition (r = -.11, p < .001), psychomotor functioning (r = .13, p < .001), and verbal ability (r = -.09, p = .007), suggesting that higher levels of
anxiety correspond to higher levels of depression and poorer performance in all cognitive
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domains. Additionally, all test scores correlated meaningfully with one another at the p <
.001 level. This finding justifies the examination of a global cognition score that takes
broader cognitive performance into account. This also served as a basis to create
aggregate scores for the cognitive domains of psychomotor functioning and verbal
ability. Similarly, all the depression subscales that comprise the aggregate depression
score correlated with one another.

Hierarchical regression analyses were performed in order to determine the impact
of three groups of participants with respiratory disease (all, asthma, COPD) on global
cognition, after controlling for the comorbidities of cardiovascular disease and
depression. Preliminary analyses were conducted to ensure no violation of regression
assumptions. Cardiovascular disease and depression were entered in the first step and
respiratory disease group in the second step. As shown in Table 3, comorbidities (i.e.,
cardiovascular disease, depression) explained 4% of the variance in global cognition
scores. Diagnosis of cardiovascular disease and higher depression scores were associated
with poorer performance on overall cognition, β = -.07, p = .028 and β = -.18, p <.001,
respectively. After entering respiratory disease at Step 2, the total variance explained by
the model was 5%, F(3, 958) = 14.82, p < .001. Respiratory disease accounted for only
an additional 1% of variance in the final model, β = .10, p = .002. Although small in
effect, in the final model, all three variables, cardiovascular disease, depression, and
respiratory disease, were statistically meaningful. Individual Beta values, standard errors,
p-values, and change in R-squared can be found in Table 3. It is important to note that,
contrary to hypothesis, those with respiratory disease were found to indicate better global
cognitive performance.
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To account for possible differences between groups of the most common
respiratory diseases, asthma and COPD, hierarchical regressions were rerun two more
times, entering asthma and COPD, respectively, into Step 2. Results can be found in
Table 3. For both regression analyses, comorbidities (i.e., cardiovascular disease,
depression) again explained 4% of the variance in global cognition scores. Diagnosis of
cardiovascular disease and higher depression scores were associated with poorer
performance on overall cognition. The first model revealed that cardiovascular disease
and depression predicted global cognition scores for both asthma, F(2, 888) = 17.88, p <
.001, and COPD, F(2, 868) = 18.90, p < .001, but after entering respiratory groups in
Step 2, no additional variance was explained by the model and no meaningful effect was
found for asthma (p = .131) or COPD (p = .106) on global cognition.

Hierarchical regression analyses were also conducted to determine the relative
impact of cardiovascular disease, depression, and respiratory group on psychomotor
functioning. As with earlier analyses, cardiovascular disease and depression were
entered in the first step and respiratory disease group in the second step. As shown in
Table 4, comorbidities (i.e., cardiovascular disease, depression) explained 5% of the
variance in psychomotor functioning scores. Diagnosis of cardiovascular disease and
higher depression scores were associated with poorer performance on psychomotor tasks,
β = -.12, p < .001 and β = -.18, p < .001, respectively. This model revealed predictive
power of these comorbidities on psychomotor functioning, F(2, 924) = 18.18, p < .001.
Step 1 remained statistically meaningful in explaining variance in psychomotor
functioning in regression analyses examining asthma (4%), F(2, 854) = 21.94, p < .001,
and COPD (5%), F(2, 833) = 21.81, p < .001, independently. However, in all three
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regressions, Step 2, that is, including respiratory group in the predictive model to explain
psychomotor scores, did not explain additional variance in scores, suggesting no
relationship between respiratory disease and psychomotor functioning when controlling
for the effects of cardiovascular disease and depression.

One final set of hierarchical regression analyses were performed in order to
determine the impact of three groups of participants with respiratory disease (all, asthma,
COPD) on verbal ability, after controlling for the comorbidities of cardiovascular disease
and depression. Cardiovascular disease and depression were entered in the first step and
respiratory disease group in the second step. As shown in Table 5, this model differed
from regressions examining overall cognition and psychomotor ability in that
comorbidities (i.e., cardiovascular disease, depression) only explained 2% of the variance
in verbal ability scores and that even this effect was carried by depression, β = -.14, p <
.001; F(2, 956) = 11.16, p < .001, and cardiovascular disease did not appear to share a
meaningful relationship with verbal ability. After entering respiratory disease at step 2,
the total variance explained by the model was 3%, F(3, 955) = 11.88, p < .001. All
respiratory disease accounted for only an additional 1% of variance in the final model, β
= .11, p < .001, revealing that respiratory disease diagnosis was related to higher verbal
performance. In step 2, depression (p < .001) and respiratory disease (p < .001)
meaningfully predicted verbal ability, whereas cardiovascular disease showed a possible
trend (p = .059). As described, presence of comorbidities was related to poorer
performance and presence of respiratory disease was related to better performance.
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To further explore the unanticipated finding of respiratory disease predicting
better verbal ability, hierarchical regressions were once again conducted two additional
times, entering asthma and COPD, respectively, into Step 2. Results can be found in
Table 5. For both regression analyses, comorbidities explained 3% of the variance in
verbal ability, again carried primarily by depression, such that higher depression scores
indicated poorer verbal ability in step 1 of regressions that examined asthma, F(2, 884) =
11.53, p < .001, and COPD, F(2, 864) = 11.51, p < .001. However, in examining the
additive predictive effect of COPD on verbal ability, it was found that, although the
additional variance explained by this model was minimal (< 1%), COPD was
meaningfully related to better verbal ability. Unlike with COPD, asthma offered no
additional predictive effect on verbal ability.

To explore further, additional multiple regressions were executed testing for
moderation. All nine multiple regressions previously conducted (predicting scores on the
three cognitive domains for three groups of respiratory disease) were re-run two more
times, entering interaction terms for respiratory disease X cardiovascular disease and
respiratory disease X depression, respectively into Step 3 of the regression analyses.
Results of analyses revealed that interactions of the respiratory disease groups with
cardiovascular disease and depression did not add any meaningful incremental prediction
of cognitive scores for any of the domains (ps > .05).

Means and standard deviations for physiological variables are reported in Table 6,
along with clinical norms for an older adult population compiled from medical sources
(Beasley et al., 2017; McCance & Huether, 2018; Whelton et al., 2018). With the
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exception of systolic blood pressure, physiological measures (diastolic blood pressure,
respiration, and oxygen saturation) were found to be in the normal range for all groups.
Systolic blood pressure was found to be in the range consistent with Stage 2
hypertension, not unexpected given that about 70% of the total sample reported
diagnosed cardiovascular disease. Additionally, no meaningful differences between the
respiratory and cardiovascular groups and their reference groups were found, except that
those with self-reported cardiovascular disease had higher systolic blood pressure than a
reference group without cardiovascular disease, t(957) = 1.84, p = .02, an expected and
small effect. Correlations were run to explore relationships between physiological
measures and cognitive domains, also revealing no meaningful relationships between any
of the physiological measures and the three cognitive domains.
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Discussion
The primary goals of the current study were to examine the relationship between a
group of common respiratory diseases (asthma, COPD, sleep apnea, and pulmonary
fibrosis) and global cognition, psychomotor functioning, and verbal ability in older
adults, while also evaluating the impact of cardiovascular disease, depression, and
anxiety in this relationship. It was hypothesized that cardiovascular disease and
depression would both correlate with poorer cognitive functioning in all domains and
that, after controlling for cardiovascular disease and depression, a relationship between
respiratory disease and poorer functioning would emerge, with COPD demonstrating a
stronger effect as compared to asthma.

Regarding predictions about cardiovascular disease, the research largely
supported the hypotheses. Cardiovascular disease was related to poorer performance on
global cognition, which, when further broken down into the domains of psychomotor
functioning and verbal ability, appeared to limit the effect to psychomotor functioning.
Although a stronger effect was correctly predicted in the psychomotor domain, it was
also expected that the effect would translate to verbal ability, which was not the case
when verbal ability was examined apart from global cognition. As an aside, this may be
consistent with the oft-cited distinction between crystallized and fluid intelligence, that
crystallized intelligence can remain intact even in cognitively compromised populations,
whereas fluid intelligence may decline sooner in compromised populations or in tandem
with normal aging (Horn & Cattell, 1967). With regard to depression, hypotheses were
fully supported. Depression predicted poorer functioning in global cognition, as well as
when broken down into the domains of psychomotor and verbal ability. The effects of
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cardiovascular disease and depression remained essentially unchanged across analyses of
all included respiratory diseases, asthma alone, and COPD alone. Although the combined
impact of cardiovascular disease and depression was meaningful, the effect was minimal.
Only 2-3% of the variability in verbal ability scores and 4-5% in psychomotor scores was
explained by cardiovascular disease and depression.

Although when controlling for the noted effects of cardiovascular disease and
depression, respiratory disease was found to meaningfully predict global cognition
scores, it predicted better, not poorer, performance, contrary to hypothesis. This effect
was also small, explaining only an additional 1% of variability in scores. Additionally,
when examining this effect comparing asthma and COPD separately, neither one
produced a significant effect on its own. Only the all-inclusive respiratory group
exhibited the counterintuitive result. Further investigation revealed that with respect to
psychomotor functioning, respiratory disease offered no statistical predictive quality on
top of cardiovascular disease and depression. However, respiratory disease did add
predictive quality over the comorbidities in the domain of verbal ability, possibly
accounting for the effect seen in global cognition (which is comprised of verbal ability
and psychomotor domains together). Furthermore, when comparing asthma to COPD in
prediction of verbal ability scores, asthma alone did not appear to have an effect, whereas
the COPD group seemed to account for the minimal effect predicting better verbal ability.

In summary, the only truly notable impact of respiratory disease on cognition was
in the domain of verbal ability and the effect was a beneficial one, and more likely to be
associated with COPD than asthma. This effect is counterintuitive, not only because the
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direction of the relationship runs counter to previous research (e.g., Caldera-Alvarado et
al., 2013; Dodd, 2015; Moss et al., 2005; Salık et al., 2007) and theoretical expectations,
but especially because COPD, the more severe of the two types of respiratory disease,
was the one that appears to account for the positive effect on verbal ability. Although it is
possible to dismiss this finding because the statistical significance is borderline, the effect
is minimal, and one could easily conclude that the current study is consistent with the
research that respiratory disease in the elderly does not have a detectable impact on
cognitive functioning, there may be a possible explanation for this effect. As noted
earlier, some researchers have found that corticosteroid use can actually enhance some
cognitive abilities, among them expressive language (Bozek et al., 2010; Prado & Crowe,
2019). Due to the severe nature of COPD relative to asthma, corticosteroid use may be
more frequent and perhaps this could explain the presence of a beneficial effect only for
the COPD group and only for verbal ability in contrast to psychomotor functioning.
Nonetheless, this is speculative as no data for medications or disease management were
included in this study. Whatever the reason, these findings seem to indicate contrary to
the approach of Yáñez et al. (2014) that COPD and asthma are essentially the same
disease in the elderly, as differences were observed in the current research when
contrasting asthma and COPD subgroups. It could be suggested that the disease types are
similar with respect to their pathophysiology, but their clinical presentations and severity
appear to remain different.

Regarding secondary aims/hypotheses, as expected, both anxiety and depression
were associated with poorer cognition, globally and within both the psychomotor and
verbal domains. Additionally, all individual cognitive tests that compromised the
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domains correlated with another, as expected, allowing for creation of the aggregate
domain scores, but also affirming data integrity in the process.

An additional aim of this research was to explore the relationship between
physiological measures known to correlate with heart and respiratory disease and to
examine their impact on cognition. A study of the whole sample, as well as isolating the
cardiovascular and respiratory groups, revealed that on average, physiological measures
were in the normal range for diastolic blood pressure, oxygen saturation, and respiration
(breaths per minute). The exception, systolic blood pressure, was found to have a mean
on the cusp of hypertensive disease, which is consistent with a sample whose majority
has been diagnosed with cardiovascular disease/hypertension. Nonetheless, none of these
measures appeared to relate to the cognitive domains in a meaningful way. Also, aside
from those with cardiovascular disease showing higher systolic blood pressure than a
reference group without it, no other differences on these measures were found between
those with and without cardiovascular disease and with and without respiratory disease. It
is likely to infer from this that, although these groups of people had self-reported
diagnoses of disease, diseases were either well-controlled by medical treatment or the
severity of disease was mild, thus reflecting generally normal levels of physical disease
indicators. This may also lend understanding as to why, by and large, meaningful
relationships did not emerge between respiratory disease and neuropsychological
functioning and why the effect size was smaller than anticipated, even for the
associations between cardiovascular disease and depression on cognition. Perhaps more
meaningful associations may have been observed in a sample of patients with greater
disease severity.
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Another point to consider regarding the failure to identify the expected negative
relationship between respiratory disease and cognitive performance is that some have
observed that asthma is underdiagnosed in the elderly (Banerjee et al., 1987; Stupka &
deShazo, 2009). If this position is considered, it is possible the reference group utilized as
a control for respiratory disease, a group of participants that was assumed to be cleared
from diagnoses of respiratory diseases, may have, in fact, included those with undetected
asthma, thereby skewing the results.

Limitations, Challenges, and Future Directions

Aside from those already alluded to, a number of limitations exist that may have
impacted the extent of the findings or prevent generalization to clinical settings. Firstly,
and perhaps most importantly, data on disease severity and treatment regimens were not
obtained as part of this research. Data on reported severity may have been informative
with respect to interpreting results and would have likely provided more context for the
physiological data obtained. Additionally, accounting for the effects of medications, such
as corticosteroids, may have provided more insight into results, as well. Another
limitation may be the bias resulting from the “presenting problems” of the participants.
As noted, MERI participants presented for neuropsychological testing primarily due to
subjective memory or other cognitive complaints or out of concern due to aging and a
family history of dementia or Alzheimer’s disease. Although medical history was
examined peripherally, the focus of the parent research was not to validate the diagnoses
of respiratory or cardiovascular disease nor to recruit from medically unstable
populations. As mentioned, it is possible that recruitment of participants from pulmonary
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or cardiovascular specialty clinics may have been more appropriate for this type of
research.

Another methodological downside using the MERI data for the current project is
that neuropsychological test selection was intended to be sensitive to more basic
cognitive changes typically associated with dementia and Alzheimer’s disease. Perhaps
the impact of respiratory disease on cognition via cerebral oxygen deprivation may be
more subtle and require more sensitive tests or comprehensive tests of higher-order
functioning (e.g., Delis-Kaplan Executive Function System [DKEFS; Delis et al., 2012]).
This is compounded by the fact that in an older adult population, the effects of normal
cognitive aging may also be at play. Additionally, a challenge in all neuropsychological
assessment is that often, an individual test may correlate with or assess multiple domains,
complicating the interpretation of findings. For example, the Category Fluency test in the
current study is conventionally used as a measure of verbal ability but is also widely used
as a measure of executive functioning, possibly confounding the results. A research
program focused more narrowly on the effects of respiratory disease may take these
considerations into account.

Finally, the current study only evaluated data at a single timepoint. Comparison of
baseline functioning with performance at future visits, along with physiological measures
obtained on multiple occasions, may provide a clearer picture of the clinical implications
of medical disease on cognition.
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Clinical Implications and Applications

There are numerous clinical implications of the current study. The relatively little
the scientific community knows about how respiratory disease impacts
neuropsychological functioning, let alone, in conjunction with comorbid conditions also
known to impact functioning, can now benefit from expanded knowledge. Although
results may be limited by the factors outlined above, in the current investigation the
following basic pattern emerges: 1) depression relates to poorer cognition, globally, and
within the individual domains of verbal ability and psychomotor functioning 2)
cardiovascular disease relates to poorer functioning most significantly in the domain of
psychomotor functioning 3) respiratory disease does not appear to explain cognitive
performance, with the possible exception of COPD relating to enhanced performance in
verbal ability. These findings can prepare medical practitioners to anticipate, as well as
appropriately screen for neuropsychological impairment in the related domains.
Monitoring and screening could then inform treatment planning and development of
compensatory cognitive strategies, when indicated. For example, a patient who presents
to a medical professional and is diagnosed with COPD may also be screened for
depression and cardiovascular disease. Depending on the results, practitioners may want
to refer for additional screening for deficits in either verbal or psychomotor domains. A
patient with heart disease may be educated to apply extra caution when engaging in
potentially hazardous motor-related tasks or be guided to maximize on the likelihood of
preserved verbal and language functions in personal or professional settings.
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Recently, the global COVID-19 pandemic has resulted in many infected patients
presenting with oxygen deprivation secondary to hypoxic conditions not unlike those
seen in asthma or COPD (Rahman et al., 2021). It has yet to be seen how COVID-19 may
relate to cognition, especially longitudinally, but future research utilizing the theoretical
framework outlined in this study may prove useful.
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Tables

Table 1
Means and Standard Deviations of Neuropsychological Test Raw Scores and Z-scores
for Aggregate Depression and Anxiety by Group
All
Respiratory
Cardiovascular
Participants
Disease
Disease
n = 969
n = 196
n = 678
Neuropsychological Tests

M (SD)

M (SD)

M (SD)

MMSE

26.60 (4.80)

27.44 (3.76)

26.57 (4.72)

AVLT-Total Recall

36.16 (14.03)

38.40 (12.34)

35.34 (13.67)

Verbal Fluency (FAS)

37.00 (16.79)

40.22 (17.23)

36.39 (17.26)

Category Fluency

14.63 (6.84)

16.37 (7.07)

14.37 (6.95)

Boston Naming

22.89 (6.50)

23.87 (5.92)

22.73 (6.45)

Vocabulary

11.05 (3.00)

11.41 (2.78)

11.06 (3.00)

Trail Making Test A

50.85 (30.04)

47.58 (26.34)

52.53 (31.12)

Trail Making Test B

115.91 (65.44)

112.59 (63.89)

119.87 (67.20)

Digit Symbol

38.72 (14.38)

39.08 (14.63)

37.42 (14.14)

Grooved Pegboard (DH)

110.52 (44.17)

108.98 (38.93)

112.68 (43.52)

Grooved Pegboard (non DH)

121.16 (47.88)

123.19 (44.99)

124.07 (47.26)

Depression

-.01 (.86)

.14 (.91)

.01 (.89)

Anxiety

-.02 (.84)

.09 (.90)

.00 (.85)

Aggregate Z-scores

Note. For the following tests, higher scores represent poorer performance (i.e., time, in
seconds, to complete the task): Grooved Pegboard, TMTA, TMTB. For all other tests,
higher scores indicate better performance. For depression and anxiety, higher z-scores
indicate greater disease severity.
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Table 2
Correlation Coefficients of Neuropsychological Test Scores
1
2
3
4
5
6
7
8
9 10
1. AVLT-Total
1
2. VF (FAS)
.56*
1
3. VF (Animals)
.66* .65*
1
4. Boston Naming
.58* .55* .70*
1
5. Vocabulary
.52* .60* .59* .65*
1
6. TMT-A
.49* .45* .56* .52* .39*
1
7. TMT-B
.47* .46* .52* .45* .38* .67*
1
8. Digit Symbol
.63* .59* .67* .61* .49* .72* .66* 1
9. GP (DH)
.40* .27* .40* .37* .31* .48* .43* .50* 1
10. GP (non DH)
.34* .28* .37* .32* .24* .43* .46* .47* .75* 1
Note. * p  .001; AVLT = Auditory Verbal Learning Test; VF = Verbal Fluency; TMT =
Trail Making Test; GP = Grooved Pegboard); DH = dominant hand
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Figures

Figure 1. Display of test aggregates for neuropsychological domains
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Figure 2. Number of participants with and without diagnoses of cardiovascular and
respiratory disease.
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